Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C60H72N8O6.2H2O |
| Molecular Weight | 1037.2942 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.COC(=O)N[C@@H](C(C)C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=CC=C(C=C4N3)C5=CC6=CC=C5CCC7=CC=C(CC6)C(=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]%10C[C@@H]%11CCCC[C@@H]%11N%10C(=O)[C@@H](NC(=O)OC)C(C)C
InChI
InChIKey=HNVFJWRQGPHREH-KDRULICVSA-N
InChI=1S/C60H72N8O6.2H2O/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6;;/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72);2*1H2/t41-,42-,49-,50-,51-,52-,53-,54-;;/m0../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C60H72N8O6 |
| Molecular Weight | 1001.2637 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Odalasvir (previously known as ACH-3102) is a second-generation inhibitor of the nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It was reported that HCV NS5A is associated with interferon signaling related to HCV replication and hepatocarcinogenesis. HCV NS5A inhibitors efficiently inhibited HCV replication. It is known that HCV is a leading cause of hepatocellular carcinoma (HCC) in Japan and is one of the major causes of end-stage liver disease, HCC, and liver transplantation in the United States and Europe. Odalasvir completed phase II clinical trial, where was evaluated efficacy and safety of its combinations with AL-335, and simeprevir in the treatment of chronic hepatitis C Infection.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. | 2018-12 |
|
| Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach. | 2018-10-22 |
|
| Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones. | 2018-10 |
|
| Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. | 2018-06 |
|
| Hepatitis C virus NS5A inhibitors and drug resistance mutations. | 2014-03-21 |
|
| Meeting report: 26th International Conference on Antiviral Research. | 2013-10 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:21:44 GMT 2025
by
admin
on
Wed Apr 02 11:21:44 GMT 2025
|
| Record UNII |
5PST6985SZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000042551
Created by
admin on Wed Apr 02 11:21:44 GMT 2025 , Edited by admin on Wed Apr 02 11:21:44 GMT 2025
|
PRIMARY | |||
|
5PST6985SZ
Created by
admin on Wed Apr 02 11:21:44 GMT 2025 , Edited by admin on Wed Apr 02 11:21:44 GMT 2025
|
PRIMARY | |||
|
140780042
Created by
admin on Wed Apr 02 11:21:44 GMT 2025 , Edited by admin on Wed Apr 02 11:21:44 GMT 2025
|
PRIMARY | |||
|
2090706-83-3
Created by
admin on Wed Apr 02 11:21:44 GMT 2025 , Edited by admin on Wed Apr 02 11:21:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |